Abstract | BACKGROUND: METHODS: PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systematically searched, and we included randomized controlled trials assessing the effect of ranibizumab addition on patients with diabetic retinopathy for this meta-analysis. RESULTS: Six randomized controlled trials were finally included in the meta-analysis. Overall, compared with control intervention for diabetic retinopathy, ranibizumab addition showed significantly increased number of neovascularization area reduction (OR = 4.20; 95% CI = 1.47-12.02; P = .007) and reduced fluorescein leakage (MD = -2.53; 95% CI = -3.31 to -1.75; P < .00001), but showed no obvious impact on neovascularization area (MD = -1.80; 95% CI = -3.68 to 0.08; P = .06), photocoagulation retreatment (OR = 1.03; 95% CI = 0.47-2.27; P = .94) or adverse events (OR = 1.45; 95% CI = 0.49-4.29; P = .50). CONCLUSIONS:
|
Authors | Hongli Yin, Senquan Zhong |
Journal | Medicine
(Medicine (Baltimore))
Vol. 102
Issue 31
Pg. e34170
(Aug 04 2023)
ISSN: 1536-5964 [Electronic] United States |
PMID | 37543834
(Publication Type: Systematic Review, Meta-Analysis, Journal Article)
|
Copyright | Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. |
Chemical References |
- Ranibizumab
- Angiogenesis Inhibitors
- Bevacizumab
- Vascular Endothelial Growth Factor A
|
Topics |
- Humans
- Ranibizumab
(therapeutic use)
- Diabetic Retinopathy
(complications, drug therapy, surgery)
- Angiogenesis Inhibitors
(therapeutic use)
- Bevacizumab
(therapeutic use)
- Vascular Endothelial Growth Factor A
(therapeutic use)
- Laser Coagulation
- Intravitreal Injections
- Diabetes Mellitus
(drug therapy)
|